Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2025-05-05T13:01:53.540167Z
Market Cap
3.90M

Momentum Score

…

Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies. In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription. The company operates retail stores under the Delta 9 brand name across the Canadian provinces. It also exports its products to Australia. Delta 9 Cannabis Inc. was incorporated in 2001 and is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
71.15M
Revenue Per Share
0.43
Gross Profit TTM
17.32M
Debt / Equity
-
ROE
-256.71%
Net Debt
41.88M
ROCE
-55.14%
Diluted EPS TTM
-0.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -27.84M -11.54M -5.08M 13.52M -8.58M
Minority interest 0.64M -0.04M 0.93M -0.01M -0.15M
Net income -27.20M -11.18M -6.42M 13.74M -8.49M
Selling general administrative 19.87M 19.07M 15.97M 14.60M 11.68M
Gross profit 10.88M 17.32M 18.00M 16.40M 5.74M
Reconciled depreciation 7.97M 6.48M 5.31M 3.55M 0.96M
Ebit - -7.64M -2.77M -5.04M -8.50M
Ebitda -13.36M -1.17M 3.43M 18.87M -7.52M
Operating income -20.26M -7.64M -2.23M -2.20M -8.50M
Interest expense 6.51M 3.90M 3.20M 1.81M 0.11M
Tax provision 0.00M -0.40M 0.40M - -
Interest income 0.12M 0.03M 0.04M 0.06M 0.23M
Net interest income -6.98M -4.27M -3.15M -1.76M 0.12M
Income tax expense - -0.40M 0.40M - -
Total revenue 63.23M 62.29M 52.05M 31.77M 7.57M
Total operating expenses 83.49M 69.93M 54.28M 33.97M 16.07M
Cost of revenue 52.35M 44.97M 34.05M 15.36M 1.83M
Total other income expense net -0.60M 0.36M 0.30M 17.47M -0.20M
Net income from continuing ops -27.84M -11.14M -5.49M 13.52M -8.58M
Net income applicable to common shares - -11.18M -6.42M 10.90M -8.49M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 89.55M 74.78M 76.40M 66.16M 45.98M
Intangible assets - 0.15M 0.15M - -
Other current assets 0.38M 0.71M 0.64M 0.76M 0.66M
Total liab 83.01M 49.50M 41.56M 31.73M 10.67M
Total stockholder equity 6.56M 24.67M 35.00M 34.44M 35.46M
Other current liab - 1.44M 0.96M 0.24M 0.17M
Common stock - 64.08M 62.27M 55.38M 53.16M
Capital stock 72.58M 64.08M 53.16M 55.38M 53.16M
Retained earnings -54.57M -27.37M -17.11M -10.70M -21.14M
Other liab - 1.19M 1.17M - -
Good will 14.20M 2.91M 0.66M - -
Other assets - 0.27M 0.51M - 2.76M
Cash 3.52M 0.94M 8.08M 5.85M 16.23M
Total current liabilities 52.81M 40.30M 15.77M 11.40M 5.75M
Net debt 41.88M 12.87M 15.00M 13.26M -
Short long term debt 29.81M 11.34M 0.15M 0.59M 0.48M
Other stockholder equity - -17.82M -18.31M -17.76M 0.69M
Property plant equipment - 40.21M 41.60M 37.00M 16.77M
Total current assets 27.20M 30.72M 32.52M 24.66M 26.38M
Long term investments 0.53M 0.53M 0.93M 1.15M 2.76M
Net tangible assets - 21.62M 31.17M 31.09M 35.39M
Net receivables 2.32M 5.57M 5.27M 6.02M 1.97M
Long term debt 15.59M 2.48M 22.93M 18.51M 4.92M
Inventory 19.82M 23.43M 18.53M 12.03M 7.09M
Accounts payable 2.53M 3.05M 1.85M 0.37M 4.77M
Non current assets total 62.35M 44.06M 43.88M 38.19M 19.60M
Capital lease obligations 20.74M 12.17M 10.69M 8.58M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -13.87M 0.89M 0.89M -0.03M -3.00M
Change to liabilities - 5.80M 4.28M -2.30M 4.78M
Total cashflows from investing activities - -2.86M -6.32M -14.07M -20.52M
Net borrowings - -4.10M 2.13M 14.60M 5.39M
Total cash from financing activities 16.80M -3.50M 7.04M 15.81M 22.03M
Change to operating activities - -0.96M -0.44M 0.25M -1.29M
Net income -27.20M -11.18M -6.42M 10.90M -8.49M
Change in cash -0.72M -7.13M 2.23M -10.38M -7.32M
Begin period cash flow 4.24M 8.08M 5.85M 16.23M 23.55M
End period cash flow 3.52M 0.94M 8.08M 5.85M 16.23M
Total cash from operating activities -3.66M -0.78M 1.51M -12.13M -8.83M
Issuance of capital stock 1.72M 0.00M 5.01M 1.15M 16.71M
Depreciation 7.97M 6.46M 5.29M 3.52M 0.94M
Change to inventory 1.58M -5.67M -6.42M -4.68M -2.12M
Change to account receivables 1.80M 0.49M 0.49M -3.70M -1.71M
Other cashflows from financing activities - 0.60M -0.09M 0.07M -0.08M
Change to netincome - 4.68M 4.30M -16.15M -0.96M
Capital expenditures 2.36M 2.58M 5.84M 14.03M 16.79M
Change in working capital 7.62M -0.75M -1.69M -7.98M -0.34M
Stock based compensation 1.62M 1.46M 1.62M 1.44M -
Other non cash items 5.60M 3.18M 1.75M -5.25M -3.73M
Free cash flow -6.02M -3.35M -4.33M -26.16M -26.35M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR
-0.34
1.04%
32.49 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-2.10
1.27%
163.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.15
0.71%
21.42 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.05 - 10.66 0.01 1.16 2.94 23.11

Profile*

Delta 9 Cannabis Inc

Delta 9 Cannabis Inc., together with its subsidiaries, operates as an integrated cannabis company. The company engages in the cultivation, processing, extraction, wholesale distribution, retail, and sale of medical and recreational cannabis products. Its products include dried cannabis flowers, pre-rolls, and dried sift cannabis, as well as oils, and extracted and derivative products. The company also offers grow pods and live plants to other licensed and pre-licensed companies. In addition, it operates as a medical clinic that provides physician consultation services to patients seeking a medical recommendation for a cannabis prescription. The company operates retail stores under the Delta 9 brand name across the Canadian provinces. It also exports its products to Australia. Delta 9 Cannabis Inc. was incorporated in 2001 and is based in Vancouver, Canada.

P.O. Box 68096, Winnipeg, MB, Canada, R3L 2V9

855 245 1259

202

Name Title Year Born
Mr. John William Arbuthnot IV Co-Founder, CEO & Director 1990
Mr. John William Arbuthnot III Co-Founder & Director 1954
Mr. James Lawson CFO, Controller & Sec. 1952
Mr. Mark Jonker Chief Operations Officer NA
Mr. Matthew Sodomsky Chief Technology Officer NA
Mr. Derek Reimer VP of Compliance NA
Mr. Marshall Posner Chief Marketing Officer NA
Dr. David M. Kideckel M.B.A., MBA, Ph.D. Exec. VP and Head of Strategy, Corp. Devel. & Capital Markets 1980
Mr. Ian Chadsey VP of Corp. Affairs NA
Ms. Alexa Goertzen Sr. Exec. Assistant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…